IL17RA and psoriasis: By this unique mechanism, brodalumab binds IL-17RA and inhibits signaling of IL-17 isoforms, in addition to IL-17A and IL-17A/F, providing high efficacy, fast onset of action, and high probability of complete psoriasis clearance.